Clinical Trial Update: Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase III trial of lenalidomide and dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma completed; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Lymphoma, Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2017-01-05